Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin after trauma to prevent PTSD symptoms
NL-OMON39401Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2012
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-traumatic stress disorder (PTSD) comparing Intranasal oxytocin with Intranasal placebo (2 arms). Primary endpoints: PTSD symptom severity at 1 month, Amygdala activation to emotional faces and 1 more. Started Apr 2012; status: active, not recruiting.
02
Drugs
oxytocin
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NL-OMON39401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39401.